Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2023-02-03
DOI
10.1080/14737140.2023.2168647
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression
- (2021) Evan W. Warner et al. CLINICAL CANCER RESEARCH
- Differential Treatment Outcomes in BRCA1/2 ‐, CDK12 ‐, and ATM ‐Mutated Metastatic Castration‐Resistant Prostate Cancer
- (2021) Daniel H. Kwon et al. CANCER
- Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination
- (2021) Liancheng Fan et al. JOURNAL OF UROLOGY
- Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone‐sensitive prostate cancer
- (2021) Emily Nizialek et al. PROSTATE
- CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer
- (2021) Hanqi Lei et al. Cell Death & Disease
- Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics
- (2020) Bastien Nguyen et al. EUROPEAN UROLOGY
- Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome
- (2020) Meijia Liu et al. PATHOLOGY RESEARCH AND PRACTICE
- Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
- (2020) Elsa Bernard et al. NATURE MEDICINE
- Characterizing CDK12-Mutated Prostate Cancers
- (2020) Pasquale Rescigno et al. CLINICAL CANCER RESEARCH
- Pan‐Cancer Analysis of CDK12 Loss‐of‐Function Alterations and Their Association with the Focal Tandem‐Duplicator Phenotype
- (2019) Ethan S. Sokol et al. ONCOLOGIST
- CDK 12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS 1‐ErbB‐ PI 3K signaling
- (2019) Hee‐Joo Choi et al. EMBO REPORTS
- Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer
- (2019) Melissa A. Reimers et al. EUROPEAN UROLOGY
- Genomics of lethal prostate cancer at diagnosis and castration resistance
- (2019) Joaquin Mateo et al. JOURNAL OF CLINICAL INVESTIGATION
- Whole-genome sequencing of prostate cancer reveals novel mutation-driven processes and molecular subgroups
- (2019) Caixia Liang et al. LIFE SCIENCES
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
- (2018) Srinivas R. Viswanathan et al. CELL
- Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer
- (2018) Emmanuel S. Antonarakis NEW ENGLAND JOURNAL OF MEDICINE
- 793PDPreliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
- (2018) W Abida et al. ANNALS OF ONCOLOGY
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
- (2018) David A. Quigley et al. CELL
- Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations
- (2018) Emmanuel S. Antonarakis et al. EUROPEAN UROLOGY
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
- (2017) Jerry F. Tien et al. NUCLEIC ACIDS RESEARCH
- Ovarian Cancers Harboring Inactivating Mutations inCDK12Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications
- (2016) Tatiana Popova et al. CANCER RESEARCH
- Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range
- (2016) Dehui Luo et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Cdk12 is essential for embryonic development and the maintenance of genomic stability
- (2015) H-C Juan et al. CELL DEATH AND DIFFERENTIATION
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex
- (2015) Kingsley M. Ekumi et al. NUCLEIC ACIDS RESEARCH
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
- (2015) Xiang Wan et al. BMC Medical Research Methodology
- Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
- (2014) Poorval M. Joshi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now